Guardant Health (NASDAQ:GH) Stock: Insider Alex Azar II Sells 69 Shares

Guardant Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Director Alex Azar II sold 69 Guardant Health shares at an average price of $149.56, totaling $10,319.64. The sale was made under a pre-arranged Rule 10b5-1 plan; Azar retained 962 shares.
  • Guardant Health reported quarterly EPS of -$0.29, beating the -$0.75 consensus estimate, while revenue of $360.98 million exceeded forecasts and rose 36.1% year over year.
  • Analysts’ average rating was “Moderate Buy,” with an average price target of $190.88.
  • MarketBeat previews the top five stocks to own by December 1st.

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Alex Azar II sold 69 shares of the stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $149.56, for a total transaction of $10,319.64. Following the completion of the sale, the director owned 962 shares of the company's stock, valued at $143,876.72. This trade represents a 6.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Guardant Health Stock Performance

Shares of NASDAQ:GH traded down $0.75 during midday trading on Tuesday, hitting $143.28. The company's stock had a trading volume of 1,960,154 shares, compared to its average volume of 2,217,595. The business's 50 day simple moving average is $168.29 and its 200 day simple moving average is $133.16. The company has a market cap of $19.38 billion, a P/E ratio of -38.93 and a beta of 1.67. Guardant Health, Inc. has a 12-month low of $74.55 and a 12-month high of $191.05.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.46. The business had revenue of $360.98 million for the quarter, compared to analysts' expectations of $350.72 million. The firm's revenue was up 36.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.74) EPS. On average, sell-side analysts predict that Guardant Health, Inc. will post -3.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Guardant Health

A number of institutional investors and hedge funds have recently made changes to their positions in GH. Allworth Financial LP grew its holdings in shares of Guardant Health by 38.6% during the third quarter. Allworth Financial LP now owns 1,486 shares of the company's stock worth $265,000 after buying an additional 414 shares during the last quarter. PointState Capital LP purchased a new stake in Guardant Health during the 3rd quarter valued at approximately $176,851,000. Balance Capital Partners L.P. purchased a new stake in Guardant Health during the 3rd quarter valued at approximately $3,746,000. Lighthouse Investment Partners LLC acquired a new stake in Guardant Health during the 3rd quarter worth approximately $2,548,000. Finally, Worldquant Millennium Advisors LLC acquired a new stake in Guardant Health during the 3rd quarter worth approximately $4,982,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on GH. Sanford C. Bernstein restated an "outperform" rating and set a $210.00 price target on shares of Guardant Health in a report on Thursday, September 10th. Guggenheim increased their price target on shares of Guardant Health from $190.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday, October 1st. UBS Group boosted their target price on Guardant Health from $175.00 to $225.00 and gave the stock a "buy" rating in a research note on Wednesday, September 9th. Morgan Stanley increased their price objective on shares of Guardant Health from $185.00 to $200.00 and gave the company an "overweight" rating in a research report on Monday, October 12th. Finally, TD Cowen reiterated a "buy" rating on shares of Guardant Health in a report on Tuesday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, Guardant Health presently has an average rating of "Moderate Buy" and an average price target of $190.88.

View Our Latest Report on GH

Guardant Health Company Profile

(Get Free Report)

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.

See Also

Insider Buying and Selling by Quarter for Guardant Health (NASDAQ:GH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Guardant Health Right Now?

Before you consider Guardant Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.

While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines